avibactam sodium; ceftazidime · Abbvie · NDA 206494
Avycaz
Earliest generic entry, as listed
15 Jun 2032
Blocked by patent: US 8969566, US 9284314, US 9695122.
Listed patents · 6 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 8969566 | drug substance · sets the listed date | 15 Jun 2032 |
| US 9284314 | drug substance · sets the listed date | 15 Jun 2032 |
| US 9695122 | drug substance · sets the listed date | 15 Jun 2032 |
| US 8471025 | drug substance | 12 Aug 2031 |
| US 8835455 | drug product | 8 Oct 2030 |
| US 7612087 | drug product | 12 Nov 2026 |
Exclusivities · 1 unexpired
| NPP | new patient population | 26 Jan 2027 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 206494 · 001 · RLD | powder, intravenous | EQ 0.5GM BASE;2GM/VIAL | 15 Jun 2032 |
Expired or delisted (4)
- US 7112592 · substance, product, use U-2508 · 7 Jan 2026
- US 7112592 · substance, product, use U-3818 · 7 Jan 2026
- US 7112592 · substance, product, use U-282 · 7 Jan 2026
- US 7112592 · substance, product, use U-2244 · 7 Jan 2026